Full Press Release Details
• Company Update
• By Turn Therapeutics
• October 22, 2025
Below is a recording of Turn Therapeutics Public Shareholder Session hosted by Founder & CEO Bradley Burnam on October 22, 2025.
Share
TTRX Positive Sentiment
Recording of Public Shareholder Session – October 22, 2025
Key Takeaway: Turn Therapeutics hosted a public shareholder session on October 22, 2025, led by CEO Bradley Burnam. The session included discussions on the company's developments and featured insights from Dr. Robert Redfield, a former CDC director. Additionally, Turn Therapeutics' GX-03 technology received recognition for its innovative approach to treating atopic dermatitis.
Price reaction · baseline $4.18 (2025-10-22 close) · hit after-hours · clean, no other TTRX news in the window
day 0 close
+18.4%
day 1
+21.5%
day 3 · peak
+25.6%
Market Sentiment Analysis
POSITIVE FACTORS
- Engagement with shareholders through a public session.
- CEO's interaction with a notable health figure enhances credibility.
- Recognition of GX-03 technology in a leading publication.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceCash runway
~32 mo
Minimal dilution risk
Lead asset
GX-03
Phase 2 · Covid19
Frequently Asked Questions
What was discussed in the shareholder session?
The session included company updates and insights from CEO Bradley Burnam.
Who hosted the public shareholder session?
The session was hosted by Turn Therapeutics' Founder and CEO, Bradley Burnam.
What recognition did GX-03 technology receive?
GX-03 was named one of the 'Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment.'
Who is Dr. Robert Redfield?
Dr. Robert Redfield is a former director of the Centers for Disease Control and Prevention.